Neurizon Therapeutics Limited has released a press release.
Appendix 4C & Company Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- PharmAust enters option to license agreement with Elanco
- Appendix 4D and Half Yearly Report & Accounts
- PharmAust receives $354k R&D Tax Incentive Refund
- Appendix 4C - Quarterly Report & Shareholders Update
- Monepantel reformulation successfully improves dose & taste
Later from Neurizon Therapeutics
- Chief Executive Officer resigns
- MPL successfully reformulated for canine clinical trials
- Epichem Awarded Major US Drug Discovery Contract Extension
- Epichem gains prestigious international ISO accreditation
- Appendix 4C & Company Update - June 18
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics